- Home
- IDR vs CELC Comparison
IDR vs CELC Comparison
Compare IDR & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- CELC
- Stock Information
- Founded
- IDR 1996
- CELC 2011
- Country
- IDR United States
- CELC United States
- Employees
- IDR N/A
- CELC N/A
- Industry
- IDR Precious Metals
- CELC Medical Specialities
- Sector
- IDR Basic Materials
- CELC Health Care
- Exchange
- IDR Nasdaq
- CELC Nasdaq
- Market Cap
- IDR 378.0M
- CELC 440.0M
- IPO Year
- IDR N/A
- CELC 2017
- Fundamental
- Price
- IDR $27.87
- CELC $53.07
- Analyst Decision
- IDR Strong Buy
- CELC Strong Buy
- Analyst Count
- IDR 1
- CELC 5
- Target Price
- IDR $17.50
- CELC $53.60
- AVG Volume (30 Days)
- IDR 449.4K
- CELC 886.2K
- Earning Date
- IDR 11-03-2025
- CELC 11-13-2025
- Dividend Yield
- IDR N/A
- CELC N/A
- EPS Growth
- IDR 57.55
- CELC N/A
- EPS
- IDR 0.64
- CELC N/A
- Revenue
- IDR $30,496,328.00
- CELC N/A
- Revenue This Year
- IDR $21.91
- CELC N/A
- Revenue Next Year
- IDR $5.47
- CELC N/A
- P/E Ratio
- IDR $44.08
- CELC N/A
- Revenue Growth
- IDR 59.64
- CELC N/A
- 52 Week Low
- IDR $9.67
- CELC $7.58
- 52 Week High
- IDR $32.01
- CELC $63.06
- Technical
- Relative Strength Index (RSI)
- IDR 56.22
- CELC 52.59
- Support Level
- IDR $27.13
- CELC N/A
- Resistance Level
- IDR $32.01
- CELC $63.06
- Average True Range (ATR)
- IDR 1.95
- CELC 3.04
- MACD
- IDR -0.17
- CELC -3.14
- Stochastic Oscillator
- IDR 33.87
- CELC 84.16
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.